STOCK TITAN
  1. Home
  2. News
  3. LTRN

Lantern Pharma Inc. - LTRN STOCK NEWS

Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.

Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.

Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.

In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.

With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.

News

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2023 financial results, along with upcoming milestones, clinical trials, and developments of its AI platform, RADR®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.58%
Tags
conferences earnings
-
News

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Rhea-AI Summary
Lantern Pharma (NASDAQ: LTRN) will present at a virtual conference hosted by HCW on March 7th. CEO Panna Sharma will discuss AI-driven cancer drug discovery. Investors can register for the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
conferences
-
News

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces significant milestones in the growth and development of its RADR® AI platform for cancer drug discovery. The platform has exceeded 60 billion data points and is expected to reach 100 billion by 2024. Lantern focuses on enhancing data growth efforts in drug sensitivity, combination treatment outcomes, biomarker data in rare cancers, and synthetic lethal targets. The company aims to improve molecular optimization, feature extraction, and drug-drug interaction predictions. RADR®'s expansion enables more precise cancer therapy development, automating data collection, and curation processes efficiently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
none
News

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) achieves a significant milestone in its ADC program by developing a novel cryptophycin-based ADC with potent anti-tumor activity. The company collaborates with academic partners to create highly specific and effective ADCs for various solid tumor indications. Leveraging RADR® AI platform and a unique conjugation approach, Lantern aims to advance towards IND development in 2024, targeting unresponsive solid tumors. The cryptophycin ADC shows superior potency and tumor-killing capabilities compared to existing ADCs, offering a promising solution for cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
News

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Rhea-AI Summary
Starlight Therapeutics, a Lantern Pharma subsidiary, has announced the appointment of Marc Chamberlain, M.D. as its Chief Medical Officer. Dr. Chamberlain will oversee clinical operations and planned clinical trials for brain cancers. He brings extensive expertise in neuro-oncology and therapeutic development, which will be invaluable for advancing Starlight's AI-enabled and accelerated drug development portfolio. Starlight is focused on developing precision therapeutics for cancers with limited or no effective therapeutic options, such as pediatric and adult brain cancers. The company is preparing for recurrent glioblastoma studies and has developed a CNS penetrant wholly synthetic acylfulvene, LP-184, for targeting brain tumors. The announcement marks a significant step in the company's mission to transform oncology with AI-enabled drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
none
-
News

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) has received Orphan Drug Designation (ODD) for LP-284 from the U.S. FDA for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The drug has shown potent anti-tumor activity in preclinical models and is being developed for several aggressive B-cell NHL, including MCL and HGBL. LP-284 received its second ODD this year, making a total of five orphan designations granted to Lantern. The ODD provides seven years of market exclusivity and eligibility for expedited drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial
News

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announced FDA clearance for Phase 1 clinical trial for LP-284 in non-Hodgkin’s lymphomas, progress in Phase 2 LP-300 trial for lung cancer, and financial results for Q3 2023. The company's AI platform RADR® aims to revolutionize cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.21%
Tags
earnings
-
News

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2023 operating and financial results webcast on November 8th at 4:30 p.m. ET. The company will discuss the operating and financial results for the third quarter, as well as provide guidance on upcoming milestones, clinical trials, and developments of its AI platform, RADR®. The webcast will be led by Panna Sharma, President and CEO of Lantern Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences earnings
-
News

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Rhea-AI Summary
Lantern Pharma Inc. to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.32%
Tags
conferences
News

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Rhea-AI Summary
Lantern Pharma announces in vivo data on drug candidate LP-184 in glioblastoma, validating its potential as a therapeutic for GBM. Phase 1 trial underway. LP-184 has a global market potential of $11-13 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
none

FAQ

What is the current stock price of Lantern Pharma (LTRN)?

The current stock price of Lantern Pharma (LTRN) is $3.54 as of November 15, 2024.

What is the market cap of Lantern Pharma (LTRN)?

The market cap of Lantern Pharma (LTRN) is approximately 37.4M.

What does Lantern Pharma Inc. specialize in?

Lantern Pharma specializes in precision medicine for cancer treatment, using AI and ML to identify and treat patients who will benefit most from their therapies.

What is the RADR platform?

RADR is Lantern Pharma's proprietary AI and ML platform that uses oncology-focused data points and advanced algorithms to accelerate cancer drug development.

How does Lantern Pharma's approach reduce drug development costs?

By using biomarker-based genetic screening to target patients more likely to respond to their drugs, Lantern Pharma decreases the cost and time required for drug development.

What is the company's strategy for growth?

Lantern Pharma focuses on acquiring or partnering with promising drug and diagnostic companies to advance personalized medicine programs for cancer patients.

How does Lantern Pharma use AI in drug development?

The company uses its AI platform, RADR, to analyze oncology data and develop precision therapies more efficiently and accurately.

Who are the key collaborators with Lantern Pharma?

Lantern Pharma collaborates with world-class scientific advisors and partners to enhance its precision medicine initiatives.

What are some of Lantern Pharma's recent achievements?

Lantern Pharma has made significant advances in its precision therapies and expanded its pipeline, leveraging AI to address real-world cancer treatment challenges.

Why is precision medicine important in cancer treatment?

Precision medicine allows for more accurate targeting of treatments based on genetic markers, improving efficacy and reducing unnecessary side effects.

How does Lantern Pharma's strategy benefit cancer patients?

By focusing on precision medicine and AI, Lantern Pharma aims to deliver more effective treatments faster and at a lower cost, benefiting patients with more tailored therapies.

What is the significance of biomarker-based genetic screening?

Biomarker-based genetic screening helps identify patients who are most likely to benefit from specific treatments, improving the chances of successful outcomes.

Stock LTRN logo
Lantern Pharma Inc.

Nasdaq:LTRN

LTRN Rankings

#5005 Ranked by Market Cap
N/A Ranked by Dividends

LTRN Stock Data

37.35M
10.79M
14.75%
24.1%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DALLAS